Swaminathan Iyer, MD
Hematology · Houston, TXNPI 1063493229
Payments from drug & device makers
Across 288 payments — averaging $34,900 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$5.4M
- Merck$3.2M
- Trillium Therapeutics USA, LLC$875K
- Astrazeneca UK Limited$348K
- Pfizer$183K
- Acrotech Biopharma Inc.$23K
- plus $40K from 16 others
Across 10 payments — averaging $12,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurobindo Pharma USA, Inc.$115K
- Pfizer$5K
- Acrotech Biopharma Inc.$3K
- Bristol Myers Squibb$476
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 180 | $5,421,971 |
| Merck | 10 | $3,160,835 |
| Trillium Therapeutics USA, LLC | 25 | $874,937 |
| Astrazeneca UK Limited | 2 | $347,548 |
| Pfizer | 19 | $182,798 |
| Acrotech Biopharma Inc. | 24 | $22,555 |
| Legend Biotech USA Inc. | 3 | $18,298 |
| Novartis | 2 | $7,987 |
| Sanofi | 1 | $4,732 |
| Daiichi Sankyo Inc. | 7 | $3,865 |
| Incyte Corporation | 1 | $1,948 |
| Spectrum Pharmaceuticals Inc. | 1 | $1,294 |
| AstraZeneca | 1 | $546 |
| Vertex | 1 | $475 |
| Beigene, Ltd. | 1 | $450 |
| Kyowa Kirin, Inc. | 3 | $328 |
| Rigel Pharmaceuticals, Inc. | 2 | $178 |
| ADC Therapeutics America, Inc. | 1 | $151 |
| Stemline Therapeutics Inc. | 1 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
| Genentech, Inc. | 1 | $35 |
| Gilead | 1 | $27 |
How this compares
$10,051,127 in reported general payments places this provider in the 95th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Houston
- Modupe IdowuHouston$8.7M
- Jing YeHouston$4.4M
- Uday PopatHouston$4.4M
- Sunil PatelHouston$3.5M
- Yesid Alvarado ValeroHouston$3.2M
- Siddhartha GangulyHouston$2.4M
- Alexandra IkeguchiHouston$2M
- Miguel EscobarHouston$1.1M
- Gregory KaufmanHouston$868K
- George ChenHouston$715K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.